This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


4f3f

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
{{STRUCTURE_4f3f| PDB=4f3f | SCENE= }}
{{STRUCTURE_4f3f| PDB=4f3f | SCENE= }}
===Crystal Structure of Msln7-64 MORAb-009 FAB complex===
===Crystal Structure of Msln7-64 MORAb-009 FAB complex===
 +
{{ABSTRACT_PUBMED_22787150}}
==Disease==
==Disease==
Line 12: Line 13:
==Reference==
==Reference==
-
<references group="xtra"/><references/>
+
<ref group="xtra">PMID:022787150</ref><references group="xtra"/><references/>
[[Category: Bacillus coli migula 1895]]
[[Category: Bacillus coli migula 1895]]
[[Category: Human]]
[[Category: Human]]

Revision as of 07:41, 26 March 2014

Template:STRUCTURE 4f3f

Contents

Crystal Structure of Msln7-64 MORAb-009 FAB complex

Template:ABSTRACT PUBMED 22787150

Disease

[MSLN_HUMAN] Antibodies against MSLN are detected in patients with mesothelioma and ovarian cancer.

Function

[MSLN_HUMAN] Membrane-anchored forms may play a role in cellular adhesion.[1] [2] Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro.[3] [4]

About this Structure

4f3f is a 3 chain structure with sequence from "bacillus_coli"_migula_1895 "bacillus coli" migula 1895 and Human. Full crystallographic information is available from OCA.

Reference

  • Ma J, Tang WK, Esser L, Pastan I, Xia D. Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights. J Biol Chem. 2012 Sep 28;287(40):33123-31. Epub 2012 Jul 11. PMID:22787150 doi:http://dx.doi.org/10.1074/jbc.M112.381756
  1. ↑ Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N, Ochi N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem. 1994 Jan 14;269(2):805-8. PMID:8288629
  2. ↑ Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004 Mar 5;279(10):9190-8. Epub 2003 Dec 15. PMID:14676194 doi:http://dx.doi.org/10.1074/jbc.M312372200
  3. ↑ Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N, Ochi N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem. 1994 Jan 14;269(2):805-8. PMID:8288629
  4. ↑ Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004 Mar 5;279(10):9190-8. Epub 2003 Dec 15. PMID:14676194 doi:http://dx.doi.org/10.1074/jbc.M312372200

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/4f3f"
Personal tools